enGene Therapeutics Inc. ENGN
1.74 USD -0.02 (-1.14%)
Regular-session close
1.70 -0.04 -2.30%
After hours · Nov 20, 4:06 PM ET
1.69 Day range 1.80
1.44 52-week range 12.17
- YTD
- -80.73%
- 1 year
- -73.64%
5D -0.03 (-1.56%)
- Market cap
- 116.61M
- EPS (ttm)
- -2.07
- Shares out
- 50.98M
- Forward P/E
- -3.53
- YTD return
- -80.73%
- 1-year return
- -73.64%
- 50-day average
- 8.10
- 200-day average
- 10.01
- Enterprise value
- 30.70M
- Volume
- 556.73K
- Avg volume
- 1.11M
- Open
- 1.75
- Previous close
- 1.76
- Day's range
- 1.69 – 1.80
- 52-week range
- 1.44 – 12.17
- Beta
- -0.76
- Analysts
- Strong Buy
- Price target
- 27.00 (+1451.7%)
Key statistics
- Price / book
- 1.14
- Free cash flow
- -23.58M
- Total cash
- 257.68M
- Total debt
- 24.86M
- Return on equity
- -123.06%
- Short % of float
- 2.00%
Fundamental scorecard
4 of 25 checks passed on ENGN’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Jul 31, 2026.
Financials — quick view
ENGN Revenue — quarterly 0
ENGN Net income — quarterly -32.50M
ENGN EPS — quarterly -0.47
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Dec 23, 2024 | HC Wainwright & Co. | init | — | Buy |
| Dec 6, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Nov 27, 2024 | Raymond James | init | — | Outperform |
| Nov 18, 2024 | JMP Securities | init | — | Market Outperform |
| Sep 24, 2024 | Oppenheimer | reit | Outperform | Outperform |
About enGene Therapeutics Inc.
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). The company is based in Montreal, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- engene.com
News
enGene Therapeutics Inc. (ENGN) Presents at UBS Global Biopharma Conference 2026 Transcript Leerink Partners Upgrades enGene Therapeutics to Outperform, Announces $5 Price Target
12 Health Care Stocks Moving In Thursday's Intraday Session
This AMD Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Piper Sandler Upgrades enGene Therapeutics to Overweight, Maintains Price Target to $4
Wells Fargo Upgrades enGene Therapeutics to Overweight, Raises Price Target to $6
enGene Therapeutics Inc. (ENGN) Discusses Updated LEGEND Data and Regulatory Path for Detalimogene Transcript
12 Health Care Stocks Moving In Wednesday's After-Market Session
enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC
enGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial Milestones
Your note
Sign in to keep a note on ENGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRUNK GERALD A | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Feb 19, 2024 | 0 |
| CHEUNG ANTHONY TZEYEW | Chief Technology Officer | Conversion of Exercise of derivative security | Mar 17, 2024 | 102,873 |
| COOPER RONALD HAROLD WILFRED | Chief Executive Officer | Purchase | Sep 26, 2024 | 10,000 |
| FONDS DE SOLIDARITE DES TRAVAILLEURS DU | Beneficial Owner of more than 10% of a Class of Security | Sale | Apr 21, 2024 | 3,036,150 |
| FORBION GROWTH SPONSOR FEAC I B.V. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Oct 26, 2023 | 0 |
| GLICKMAN RICHARD M | Director | Conversion of Exercise of derivative security | May 27, 2024 | 24,675 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fcpm III Services B.v. | 17.02% | 8,677,951 | 51.72M | Sep 29, 2024 |
| VR Adviser, LLC | 7.00% | 3,565,841 | 21.25M | Sep 29, 2024 |
| Blue Owl Capital Holdings LP | 6.00% | 3,058,969 | 18.23M | Sep 29, 2024 |
| Deep Track Capital, Lp | 5.12% | 2,607,633 | 15.54M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 4.57% | 2,329,768 | 13.89M | Sep 29, 2024 |
| BVF Inc. | 4.42% | 2,251,037 | 13.42M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Strategic Series-Franklin Biotechnology Discove | 0.53% | 272,359 | 1.62M | Jul 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 27,516 | 164.00K | Oct 30, 2024 |
| Northern Small Cap Core Fund | 0.02% | 11,000 | 65.56K | Sep 29, 2024 |
